The half-life question, answered properly

There is a specific and avoidable confusion at the centre of most discussions of dose timing. A once-weekly drug with a seven-day half-life does not produce a weekly peak-and-trough cycle of the kind a daily drug produces. At steady state the fluctuation between peak and trough is modest, and the practical consequence is that moving the injection from Sunday morning to Friday evening changes very little about total exposure and quite a lot about when the most noticeable effects land.

How you get seven days out of a two-minute peptide

Three engineering strategies account for essentially every long-acting agonist on the market. The first is substitution at the DPP-4 cleavage site: replacing the alanine at position 8 with a residue the enzyme cannot process removes the fastest route of degradation. The second is acylation with a fatty-acid chain, which promotes reversible binding to serum albumin; albumin-bound drug is protected from renal filtration and enzymatic attack, and dissociates slowly to provide a circulating depot. The third is fusion to a large carrier — an immunoglobulin Fc fragment, for instance — which raises the hydrodynamic radius above the glomerular filtration threshold.

Semaglutide uses the first two, with a C18 diacid linked through a spacer. Liraglutide uses a shorter C16 chain and achieves roughly thirteen hours rather than seven days, which is a useful demonstration of how much the chain contributes. Dulaglutide takes the fusion route. The strategies are not interchangeable and they produce different distribution and clearance behaviour, not merely different durations.¹

The accumulation arithmetic, worked

For a drug given at a fixed interval, the accumulation ratio at steady state is approximately 1 / (1 − e^−kτ), where τ is the dosing interval and k is the elimination rate constant, itself 0.693 divided by the half-life. For a once-weekly drug with a seven-day half-life, τ and the half-life are equal, e^−kτ is 0.5, and the accumulation ratio is 2. In plain terms: at an unchanged weekly dose, average concentration at steady state is roughly twice what it is after the first injection.

Time to steady state depends only on the half-life, not on the dose or the interval: about 94% of steady state after four half-lives, 97% after five. For a seven-day half-life that is four to five weeks. This is why a fixed four-week escalation step exists at all — it is approximately the time required for the previous dose to stop increasing — and why escalating faster than that means escalating onto a still-rising exposure curve.

These are approximations that assume linear kinetics and complete absorption. Both assumptions are reasonable for this class and neither is exact.

A missed dose, modelled

Because exposure declines with a seven-day half-life, a single missed weekly dose leaves roughly half the accumulated concentration in circulation at the point the next dose would have been due, and roughly a quarter a week after that. That is why product labelling for once-weekly agonists generally permits taking a missed dose within a defined window and otherwise skipping it, and why a single omission rarely produces a dramatic change.

An interruption of four weeks or more is a different situation. By then concentrations have fallen to a small fraction of steady state, tolerability has substantially reset, and resuming at the previous dose means presenting the receptor with an exposure step it has not seen for a month. The clinical convention — resume lower and re-escalate — follows directly from the pharmacokinetics rather than from caution alone.²

Injection timing: what the kinetics permit

At steady state on a seven-day half-life the peak-to-trough variation across the dosing interval is modest — on the order of tens of per cent rather than folds. Moving the injection by twelve hours, or from one day of the week to another, does not meaningfully change total exposure. It does change when the highest concentrations occur relative to a person’s week.

Time to maximum concentration after subcutaneous injection is on the order of one to three days for the long-acting agonists, so an injection on Friday evening produces its concentration peak somewhere in the weekend. Whether that is desirable is a question about a person’s schedule, not about pharmacology. What the pharmacology does say is that consistency of interval matters more than consistency of hour, because the interval is what determines the accumulation ratio.

Amylin analogues are a different class

Cagrilintide is not a GLP-1 receptor agonist and it is repeatedly described as one. It is a long-acting analogue of amylin, a 37-residue peptide co-secreted with insulin from the beta cell, acting at calcitonin and amylin receptor complexes. Its effects — slowed gastric emptying, reduced food intake, satiety signalling through the area postrema — overlap substantially with GLP-1 receptor agonism, which is why the confusion persists and why the co-formulation with semaglutide is pharmacologically interesting rather than redundant.

Two mechanisms converging on the same behavioural endpoint through different receptors is the argument for combining them: the ceiling of each is set by its own receptor-mediated adverse effects, and two half-doses at different receptors may sit below both ceilings. Whether that argument survives phase 3 is an empirical question.

Delayed gastric emptying is the mechanism, not the complication

Slowed gastric emptying is frequently described as a side effect. It is more accurately described as a mechanism that becomes an adverse effect at sufficient magnitude. Delayed emptying blunts the post-prandial glucose excursion, which is part of the glycaemic benefit, and it produces early satiety, which is part of the weight effect. Beyond a threshold it produces nausea, vomiting, reflux and the sensation of food sitting undigested.

Two properties of the effect matter clinically. It is dose-dependent, and it exhibits partial tachyphylaxis: the magnitude of delay attenuates over weeks of continued exposure at a fixed dose, which is the physiological basis for the observation that tolerability improves if a dose is held rather than escalated. The residual delay at steady state is real and is the reason pre-procedural fasting guidance for this class exists at all.³

The heart-rate signal

A resting heart-rate increase of roughly two to four beats per minute is one of the most reproducible findings in the class, observed across molecules, doses and populations. The mechanism is probably direct: GLP-1 receptors are expressed in the sinoatrial node region, and receptor activation has chronotropic effects in isolated preparations.

What it means clinically is unresolved. The cardiovascular outcome trials that reported the heart-rate increase also reported reductions in major adverse cardiovascular events, so whatever the chronotropic effect represents it is not overwhelming the benefit in the populations studied. That is a statement about trial populations and event rates, not a mechanistic reassurance, and the Journal reports it as such.

Desensitisation, and what it does and does not explain

Receptor internalisation following agonist binding is well established in vitro, and the popular inference is that "the receptors get used to it", explaining plateaus. The inference outruns the evidence in two ways. First, plateaus in the trials occur at around sixty to seventy weeks and coincide closely with the point at which reduced body mass lowers energy requirement enough to re-establish balance, which is a sufficient explanation without invoking receptor changes. Second, weight regain on withdrawal is rapid and near-complete, which is difficult to reconcile with a model in which the receptor has become unresponsive.

The tolerability tachyphylaxis discussed above — the attenuation of nausea and gastric delay over weeks at a fixed dose — is separately well supported. Two different phenomena share a name, and conflating them produces confident conclusions about plateaus that the data does not license.

Why any of this belongs in a general publication

An argument could be made that receptor pharmacology is a specialist concern and that readers need practical guidance instead. The Journal’s position is the opposite, for a specific reason: almost every piece of bad advice circulating about this drug class is a mechanistic error with a practical conclusion attached.

Escalating on a fixed calendar regardless of symptoms is an error about accumulation kinetics. Splitting a weekly dose into daily fractions to reduce side effects is an error about half-life and steady state. Assuming a molecule with GIP activity is simply a stronger version of one without is an error about selectivity. Expecting weight to keep falling indefinitely is an error about energy balance. In each case the practical advice is wrong because the mechanism was misunderstood, and in each case understanding the mechanism is not much harder than memorising the rule.

A note on sources

Everything above is drawn from the peer-reviewed pharmacology and clinical literature and from regulatory assessment reports, which are more informative than the papers on questions of dose selection and exposure. Where a claim rests on in-vitro work in transfected cells, this piece says so, because the translation of such work to human physiology has failed often enough in this field to deserve a standing caveat.

Where the Journal reports a trial number it states the estimand behind it, because the treatment-policy and trial-product estimands differ by two to three percentage points in the obesity programmes and the difference is routinely lost in secondary coverage. Nothing here is a recommendation, and none of the compounds discussed as research chemicals are approved for human use.

What has actually changed in the last three years

Three things, on the Journal’s assessment. First, the demonstration that a dual agonist could produce weight reduction approaching bariatric-surgical magnitude moved the field’s expectations, and with them the design of every subsequent programme. Second, the cardiovascular and renal outcome results reframed the class from metabolic-cosmetic to cardiometabolic, which changed reimbursement arguments far more than it changed prescribing.

Third, and least remarked, the pharmacology of oral administration became tractable. That is a manufacturing and access story as much as a scientific one: an oral small molecule has a completely different cost structure, cold-chain requirement and supply profile from an injectable peptide, and if it holds up in phase 3 it will do more to change who can get treated than any of the receptor science described above.

Readers sometimes ask why a publication covering a consumer-facing drug class spends this much space on binding kinetics. The answer is that the alternative is a publication that reprints press releases with adjectives added. Mechanism is the only defence against that, and it is available to anybody willing to read a figure legend.